COVID-19 and Chemotherapy Association Holds in Pediatric Leukemia/Lymphoma
Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.
Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.
On May 15, 2024, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with follicular lymphoma.
Dyikanov et al. developed a machine learning platform that uses a simple blood test to reveal cellular compositions reflective of a person’s immune system. These compositions,…
A suspicious spot on your nipple or the surrounding breast can cause alarm. Learn what it likely is—and what you can do about it.
Preventing the feedback induction of TREX1 downstream of tumor cell STING results in robust interferon signaling and can render cancer cells vulnerable to NK and…
On May 15, 2024, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with follicular lymphoma.
Drugmakers are expanding their attack on KRAS mutations, with clinical trials now underway for therapies targeting the common G12D variant, as well as broader pan-RAS…
Fuzuloparib, with or without apatinib, improved PFS over chemotherapy in patients with previously treated, HER2-negative, BRCA-mutated breast cancer.
A retrospective analysis determined the association between various adverse effects and overall and progression-free survival in patients with HCC receiving atezolizumab plus bevacizumab.
More than 150 team members will staff the new facility when it opens in January.